CymaBay Therapeutics Inc. (CBAY)
| Market Cap | 266.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -79.21M |
| Shares Out | 84.67M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,351 |
| Open | 3.13 |
| Previous Close | 3.15 |
| Day's Range | 3.08 - 3.18 |
| 52-Week Range | 3.02 - 6.56 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 11.10 (+252.4%) |
| Earnings Date | Nov 10, 2021 |
About CBAY
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is 11.10, which is an increase of 252.38% from the latest price.
News
CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade
CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
7 Penny Stocks With the Potential to 10X in 2022
The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeare...
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies...
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies...
CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biom...
NEWARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
Webinar on Monday, November 15th, @ 4:30pm EST Webinar on Monday, November 15th, @ 4:30pm EST
CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates
CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC)
CymaBay Therapeutics to Present at Upcoming Investor Conferences
NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...
CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program
CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC). U...
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC
New Strong Sell Stocks for July 20th
AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team
CymaBay Names Lewis Stuart Chief Commercial Officer
Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC):
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...
5 Disruptive Biotech Stocks With Solid Long-Term Potential
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 St...
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secr...
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...
Implied Volatility Surging for CymaBay Therapeutics (CBAY) Stock Options
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.